In this report, we provide a regulatory and economic analysis in Europe and the US of branded generic inhalers.
Qualitative and quantitative assessment of how biomarkers can change the diagnostic and commercial landscape in Alzheimer’s disease. The analysis provides an outline of the opportunities for drug and diagnostics companies in the Alzheimer’s market.
Edit my basket
© Datamonitor 2014. All rights reserved
Terms & Conditions